ArticleScientific reports2017
Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma.Nature communications · 2026Article
- Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma.Cancers · 2026Article
- Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy.BMC cancer · 2024Article
- Precision of liver and pancreas apparent diffusion coefficients using motion-compensated gradient waveforms in DWI.Magnetic resonance imaging · 2024Article
- Notch appearance as a novel radiological predictor of transient expansion and good outcome of expanding schwannoma after radiotherapy.Discover oncology · 2024Article
- Repeatability of Quantitative Magnetic Resonance Imaging Biomarkers in the Tibia Bone Marrow of a Murine Myelofibrosis Model.Tomography (Ann Arbor, Mich.) · 2023Article
- Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.European journal of nuclear medicine and molecular imaging · 2022Article
- Angpt2/Tie2 autostimulatory loop controls tumorigenesis.EMBO molecular medicine · 2022Article
- Review
- Multiparametric MRI enables for differentiation of different degrees of malignancy in two murine models of breast cancer.Frontiers in oncology · 2022Article
- Characterization and correction of cardiovascular motion artifacts in diffusion-weighted imaging of the pancreas.Magnetic resonance in medicine · 2021Article
- Improved unsupervised physics-informed deep learning for intravoxel incoherent motion modeling and evaluation in pancreatic cancer patients.Magnetic resonance in medicine · 2021Article
- [EJNMMI research · 2021Article
- Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminary Findings.Tomography (Ann Arbor, Mich.) · 2020Article
- TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer.Cell death discovery · 2020Article
- The feasibility of b-value maps based on threshold DWI for detection of breast cancer: A case-control STROBE compliant study.Medicine · 2019Article
- A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging.European radiology experimental · 2019Article
- Observational
- MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer CellsStem cells international · 2019Article
- Pancreatic cancer detection and characterization-state of the art cross-sectional imaging and imaging data analysis.Translational gastroenterology and hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in molecular subtyping of Pancreatic Ductal Adenocarcinoma (PDAC) support individualization of therapeutic strategies in this most aggressive disease. With the emergence of various novel therapeutic strategies and neoadjuvant approaches in this quickly deteriorating disease, robust approaches for fast evaluation of therapy response are urgently needed. To this aim, we designed a preclinical imaging-guided therapy trial where genetically engineered mice harboring endogenous aggressive PDAC were treated with the MEK targeting drug refametinib, which induces rapid and profound tumor regression in this model system. Multi-parametric non-invasive imaging was used for therapy response monitoring. A significant increase in the Diffusion-Weighted Magnetic Resonance Imaging derived Apparent Diffusion Coefficient (ADC) was noted already 24 hours after treatment onset. Histopathological analyses showed increased apoptosis and matrix remodeling at this time point. Our findings suggest the ADC parameter as an early predictor of therapy response in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.